217 related articles for article (PubMed ID: 35406518)
1. Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study.
Kim BK; Cheon J; Kim H; Kang B; Ha Y; Kim DY; Hwang SG; Chon YE; Chon HJ
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406518
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Lu J; Lin X; Teng H; Zheng Y
J Clin Pharmacol; 2024 Jun; 64(6):643-651. PubMed ID: 38311835
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after Atezolizumab/Bevacizumab Failure: A real-world study.
Chon YE; Kim DY; Kim M; Kim BK; Kim SU; Park JY; Ahn SH; Ha Y; Lee JH; Lee KS; Kang B; Kim JS; Chon HJ; Kim DY
Clin Mol Hepatol; 2024 Mar; ():. PubMed ID: 38468561
[TBL] [Abstract][Full Text] [Related]
4. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
[TBL] [Abstract][Full Text] [Related]
5. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma.
Su CW; Teng W; Lin PT; Jeng WJ; Chen KA; Hsieh YC; Chen WT; Ho MM; Hsieh CH; Wang CT; Chai PM; Lin CC; Lin CY; Lin SM
Cancer Med; 2023 Mar; 12(6):7077-7089. PubMed ID: 36468578
[TBL] [Abstract][Full Text] [Related]
6. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment.
Chon YE; Cheon J; Kim H; Kang B; Ha Y; Kim DY; Hwang SG; Chon HJ; Kim BK
Cancer Med; 2023 Feb; 12(3):2731-2738. PubMed ID: 35997637
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial.
Lee YC; Huang WT; Lee MY; Tsao CJ; Feng YH
In Vivo; 2023; 37(1):454-460. PubMed ID: 36593061
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
Ben Khaled N; Möller M; Jochheim LS; Leyh C; Ehmer U; Böttcher K; Pinter M; Balcar L; Scheiner B; Weich A; Leicht HB; Zarka V; Ye L; Schneider J; Piseddu I; Öcal O; Rau M; Sinner F; Venerito M; Gairing SJ; Förster F; Mayerle J; De Toni EN; Geier A; Reiter FP
JHEP Rep; 2024 Jun; 6(6):101065. PubMed ID: 38798717
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.
Casadei-Gardini A; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Rimassa L; Presa J; Masi G; Yoo C; Lonardi S; Tovoli F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Pressiani T; Montes M; Vivaldi C; Soldà C; Piscaglia F; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Iavarone M; Di Costanzo G; Marra F; Scartozzi M; Tamburini E; Cabibbo G; Foschi FG; Silletta M; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Burgio V; Persano M; Della Corte A; Ratti F; De Cobelli F; Aldrighetti L; Cascinu S; Cucchetti A
Eur J Cancer; 2023 Feb; 180():9-20. PubMed ID: 36527976
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
[TBL] [Abstract][Full Text] [Related]
11. Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis.
Park J; Lee YB; Ko Y; Park Y; Shin H; Hur MH; Park MK; Lee DW; Cho EJ; Lee KH; Lee JH; Yu SJ; Kim TY; Kim YJ; Kim TY; Yoon JH
J Liver Cancer; 2024 Mar; 24(1):81-91. PubMed ID: 38246747
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
Rimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Salani F; Lonardi S; Piscaglia F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Schirripa M; Montes M; Vivaldi C; Soldà C; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Burgio V; Scartozzi M; Cascinu S; Casadei-Gardini A
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7565-7577. PubMed ID: 36976353
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Matono T; Kuroda H; Yata Y; Ohama H; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Yokohama K; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; ;
Oncology; 2023; 101(10):624-633. PubMed ID: 37307798
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma.
Cheon J; Yoo C; Hong JY; Kim HS; Lee DW; Lee MA; Kim JW; Kim I; Oh SB; Hwang JE; Chon HJ; Lim HY
Liver Int; 2022 Mar; 42(3):674-681. PubMed ID: 34792284
[TBL] [Abstract][Full Text] [Related]
15. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Yokohama K; Nishikawa H; Nishimura T; Shimada N; Kawata K; Kosaka H; Naganuma A; Yata Y; Ohama H; Kuroda H; Aoki T; Tanaka K; Tanaka T; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M; Kumada T;
Hepatol Res; 2024 Apr; 54(4):382-391. PubMed ID: 37983642
[TBL] [Abstract][Full Text] [Related]
17. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.
Toshida K; Itoh S; Yoshiya S; Nagao Y; Tomino T; Izumi T; Iseda N; Toshima T; Ninomiya M; Yoshizumi T
J Gastroenterol Hepatol; 2024 Mar; 39(3):576-586. PubMed ID: 38084637
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Niizeki T; Tokunaga T; Takami Y; Wada Y; Harada M; Shibata M; Nakao K; Sasaki R; Hirai F; Shakado S; Yoshizumi T; Itoh S; Yatsuhashi H; Bekki S; Ido A; Mawatari S; Honda K; Sugimoto R; Senju T; Takahashi H; Kuwashiro T; Maeshiro T; Nakamuta M; Aratake Y; Yamashita T; Otsuka Y; Matsumoto S; Sohda T; Shimose S; Murotani K; Tanaka Y
Target Oncol; 2022 Nov; 17(6):643-653. PubMed ID: 36272060
[TBL] [Abstract][Full Text] [Related]
20. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Tajiri K; Tsukada K; Tokimitsu Y; Motofuji Y; Kawai K; Muraishi N; Murayama A; Hayashi Y; Shimizu Y; Yasuda I
Oncology; 2024; 102(2):131-140. PubMed ID: 37666216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
